OTCPicks.com

FEATURED COMPANY

UNIVERSAL BIOENERGY INCORPORATED (OTC: UBRG)
"Up 12.41% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/UBRG.php

Company Profile: http://www.otcpicks.com/universal-bioenergy.htm

Universal Bioenergy, Inc. is a Mississippi-based company engaged in the production of renewable fuels through its subsidiary Universal Bioenergy North America, Inc. that operates a biodiesel refinery in Mississippi. The refinery intends to produce biodiesel fuel from various virgin vegetable oils, premium greases, and non-edible vegetable oil sources using their unique and economical process.

UBRG News:

November 7 - Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production

Universal Bioenergy, Inc. (OTC: UBRG) CEO, Dr. Richard Craven, stated, "Algae can become a prominent source of energy, and with several new algae technology companies emerging, it is a good time to form alliances. We have identified and spoken with some candidates but certainly welcome contact from interested parties. It is our goal to one day be 100% self-supplying in oil raw materials. Growing our own algae-based oil would be a step in that direction as it would reduce the influence of commodity price fluctuations on our operating costs."

Universal Bioenergy, Inc. is actively seeking relationships with algae production companies for the purpose of biodiesel and other fuel production.

FEATURED COMPANY

RONN MOTOR COMPANY (OTC: RNNM)
"Up 7.58% in morning trading and 77.50% since OTCPicks began coverage"

Detailed Quote: http://www.otcpicks.com/quotes/RNNM.php

Company Profile: http://www.otcpicks.com/ronn-motor-company.htm

Headquartered in Austin, Texas, Ronn Motor Company, Inc. is a design and manufacturing company focused on the leading edge engineering of environmentally friendly, finely built premium automobiles and technology. These technology systems include Hydrogen Fuel, Fuel cells, and Plug in-electrics will be incorporated into our automobiles and made available for aftermarket applications. Our products, coupled with RMC's core values of a strong sense of ethics, environmental sensitivity and premium quality, position the company as one of the new leaders in an automotive industry transitioning toward fuel efficiency.

RNNM News:

November 10 - Frigette's Projection of Three-Year Retail Sales of One Million Units of Ronn Motor Company's H2GO™ Real Time Hydrogen Injection System Reinforced After Strong SEMA Response

Ronn Motor Company, Inc. (OTC: RNNM) announced that after strong SEMA response, the Company is reinforcing Frigette's projection of three-year retail sales of Ronn Motor Company's proprietary H2GO(TM) Real-Time Hydrogen Injection system could be potentially one million units globally, producing retail revenues potentially of up to $1 Billion in retail sales globally within the three years.

Ronn Maxwell, CEO of Ronn Motor Company, said, "The H2GO(TM) Real-Time Hydrogen Injection system was recently unveiled by Tommy DuPont, Publisher of the world renowned 'DuPont Registry' and revealed to the world at SEMA, the world's largest and most recognized automotive aftermarket convention show. The H2GO(TM) system is the catalyst behind the world's First Eco-Exotic sports car named the 'SCORPION(TM).' The Scorpion(TM) and the H2GO(TM) system were one of the most talked about features at this year's show and received unprecedented media coverage for its one-of-a-kind Green technologies that increase fuel mileage between 15-35% on any internal combustion engine while reducing noxious emissions to nearly zero.

"We are currently finalizing Global Distribution and manufacturing contracts with Frigette which is the largest aftermarket automotive manufacturer and distributor in the U.S. with nine regional distribution centers and over 5,000 distributors. Frigette products are sold directly or indirectly to over 170,000 locations worldwide. Frigette has distribution presence in the U.S.A., Europe, China, India and Russia."

Ronn Motor Company projections are based on assumptions from Frigette directly. In a prior news release, Mr. Phillip Kreymer, Director of Marketing at Frigette, said sales of one million units over the next three years are easily within Frigette's manufacturing and distribution capabilities and with a suggested retail price of $999.00 that would possibly produce revenues in the one billion dollar range.

Frigette is supplying products to many Original Equipment vehicle manufacturers including General Motors, Ford, Honda, Isuzu, Jaguar, Mazda, Nissan, and Subaru, and has been awarded the coveted "Q1 Supplier Award" by Ford Motor Company and the "First Team Supplier Award" by Nissan Motors of America. We also supply products to thirty-nine (39) OEM Recreational Vehicle manufacturers.

Frigette quality control standards have been approved by Chrysler Motors, Ford Motor Company, General Motors, Honda, Hyundai, Isuzu, Jaguar, Mazda, Nissan, Saturn, Subaru, GAZ, VAZ, Volvo, Winnebago, and others. Frigette's distributor network and key installers number in excess of 500 and have installation capabilities to support the Frigette products to the new car dealers who do not wish to perform installations. This assures the O.E.M. manufacturer that quality products, which they have approved, can be installed on their vehicles even though the car dealer may not wish to make the installation.

FEATURED COMPANY

PERF GO GREEN HOLDINGS INCORPORATED (OTCBB: PGOG)
"Up 11.11% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/PGOG.php

Company Profile:
http://www.otcpicks.com/perf-go-green/perf-go-green.htm

Perf Go Green Holdings, Inc. is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green’s corporate name reflects its “Go Green” mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

PGOG News:

October 28 - Perf Go Green Adds Leading Supermarket Chain Hy-Vee, Inc. to Distribution Network

Perf Go Green Holdings, Inc. (OTCBB: PGOG) (“Perf Go Green”), a marketer and distributor of biodegradable plastics, announced a distribution agreement with Hy-Vee, Inc. One of the top 30 supermarket chains in the U.S., Hy-Vee operates more than 224 retail stores in the Midwest.

“Our agreement with Hy-Vee is another sign of the overwhelmingly enthusiastic reception retailers are giving our biodegradable plastic bags,” said Perf Go Green Chairman and CEO Tony Tracy. “We're especially excited about this new partnership because Hy-Vee is well-known for its commitment to sustainability and its leadership in bringing health and wellness to mainstream consumers. Perf Go Green's earth-friendly products offer a meaningful way for consumers, companies and their employees to reduce their environmental footprint.”

Perf Go Green will begin shipping its 13-gallon kitchen trash bags and its 30-gallon lawn and leaf bags to Hy-Vee in November 2008.

Founded in 1930, Hy-Vee, Inc. is an employee-owned corporation operating more than 224 retail stores in seven Midwestern states. For 2007 the company recorded total sales of $5.6 billion, ranking it among the top 30 supermarket chains and the top 50 private companies in the U.S.

Founded in November 2007, Perf Go Green premiered at the March 2008 International Home and Housewares Show in Chicago, where its products received an honor for their design quality and innovation. Perf Go Green is proud to be part of the nation's “go green” movement, which is poised to become a $500 billion market by 2009, according to Landor Associates.

Perf Go Green products incorporate recycled plastics that are combined with an Oxo-Biodegradable proprietary application method to produce the film for its bags. Based on environmental claims statements made by the manufacturer of the Oxo-Biodegradable applied to our bags, when discarded in soil and exposed to the presence of microorganisms, moisture and oxygen, we believe Perf Go Green products biodegrade within two years, decomposing into simple materials found in nature much faster than regular plastics, which can take hundreds of years to break down. Through this process and the use of recycled plastics, Perf Go Green effectively removes plastic waste from the environment. In addition, Perf Go Green trash bags utilize a unique patented dispensing system that stores the bags on the bottom of trashcans and dispenses them one at a time, similar to a tissue box.

FEATURED COMPANY

BRITE-STRIKE TECHNOLOGIES INCORPORATED (OTC: BSTI)

Detailed Quote: www.otcpicks.com/quotes/BSTI.php

Company Profile: http://www.otcpicks.com/brite-strike/brite-strike.htm

Brite-Strike Tactical Illumination Products, Inc. was started by two police officers to create world-class tactical LED flashlights that had the features that police officers and citizens need to keep them safe. Brite-Strike makes a promise to always use the latest technology, world-class components, highest design and manufacturing standards, so consumers can rely on Brite-Strike products when they are needed.

BSTI News:

November 6 - Brite-Strike Tactical Illumination Products, Inc.'s Personal Protection System to Be Featured in the Prestigious Frontgate Christmas Catalog

Brite-Strike Tactical Illumination Products, Inc. (OTC: BSTI) announced that its "Lightning Strike" Personal Protection System will be featured in Frontgate's national Christmas catalog, and that shipments for the initial order will begin this week. The product is also being carried at 28 BJ's Wholesale Club locations, which can be found at www.brite-strike.com.

"This product, for the money, may be the most effective defensive tool available for women today, particularly in preventing assaults and rapes," said Glenn Bushee, President of Brite-Strike. "The gift set includes a powerful, but compact, tactical flashlight, with the patented tactical touch hi-low-strobe switch, a leather holster, as well as a personal safety alarm, that can emit a shrieking noise of up to 125 db, and can be effective in warding off dogs and assailants. The package includes other accessories, and is packaged in a presentation gift box."

The company also announced that sales of its flagship model, the "Tactical Blue-Dot" flashlight, currently being featured in the Herrington Catalog, remain very strong, and are expected to significantly exceed last year's sales, even in this challenging economic environment. The company has been informed that its product is the top selling product in the catalog at that price-point. "In tough economic times, such as now, the number of robberies and assaults rise dramatically, which increases the demand for all our products," said Mr. Bushee, president of Brite-Strike.

In other news, the company announced that it had shipped its first order to the Pennsylvania Prison System, an area where the company see's significant growth opportunities. The company is also currently in discussions with one major national retailer for the placement of the "Lightning Strike," and is in late-stage testing with one branch of the US Military.

The company recently filed a Form 15 with the SEC. This form is in preparation for the company's financial audit, and intent to file as an SEC reporting company, with application to file for listing on the OTC BB the first half of 2009.

"We are extremely optimistic about the future of Brite-Strike. We feel the current share price dramatically undervalues the company, and its long-term growth prospects. We project dramatic increase in revenues over the next several years, both from our existing product line, as well as new products," said Mr. Bushee. "We appreciate our loyal shareholders, and in acknowledgement of their support, we would like to offer any shareholders ordering product through customer service, at 781-585-5509, a discount on all their purchases, with free gift-wrapping for all our customers for the holiday season."

FEATURED COMPANY

GREENCHEK TECHNOLOGY INCORPORATED (OTCBB: GCHK)

Detailed Quote: http://www.otcpicks.com/quotes/GCHK.php

Company Profile:
http://www.otcpicks.com/greenchek-technology/greenchek-technology.htm

GreenChek Technology, Inc. manufactures and distributes hydrogen injection technology devices that primarily focus on mobile transportation applications and industrial generative power applications. It also provides mobile greenhouse gas emissions reduction technology. The company's Onboard Hydrogen Generation and Injection technology is used for emissions reduction technology and fuel economy enhancement in trucks, locomotives, and automobile engines. It has operations in the United States, Canada, Asia, and Europe. The company, formerly known as Ridgestone Resources, Inc., was founded in 2006 and is headquartered in San Francisco, California.

GCHK News:

November 6 - GreenChek Achieves 19% to 21% Fuel Savings During In House Testing

GreenChek Technology Inc. (OTCBB: GCHK), a leading globally focused provider of hydrogen-based technology for mobile transportation and stationary power generation applications, announced today that they continue to achieve successful results through ongoing in-house testing of their Emission Reduction Device Technology.

GreenChek manufactures an emission reducing device simply known as the ERD 1.0, which can be retrofitted to any vehicle or combustible engine regardless of fuel source. This device reduces vehicle emissions as well as increases fuel economy.

“As we continue to test internally the ERD we are pleased the with the fuel reduction results,” said Donald Walling, GreenChek’s Chief Strategy Officer. “On every ERD 1.0 implementation we have noted significant improvements beyond the initial baseline testing. Average fuel savings of 19 to 21% have been achieved.”

STOCKS TO WATCH

CENTENNIAL COMMUNICATIONS CORPORATIONS (NASDAQ: CYCL)
"Up 102.86% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CYCL.php

Centennial Communications (Nasdaq: CYCL), based in Wall, NJ, is a leading provider of regional wireless and integrated communications services in the United States and Puerto Rico with approximately 1.1 million wireless subscribers and 596,700 access lines and equivalents. The U.S. business owns and operates wireless networks in the Midwest and Southeast covering parts of six states. Centennial’s Puerto Rico business owns and operates wireless networks in Puerto Rico and the U.S. Virgin Islands and provides facilities-based integrated voice, data and Internet solutions. Welsh, Carson, Anderson & Stowe is a significant shareholder of Centennial.

CYCL News:

November 7 - AT&T to Acquire Centennial Communications, Enhance Service for Wireless Customers and Businesses

AT&T Inc. (NYSE: T) and Centennial Communications Corp. (Nasdaq: CYCL) announced that AT&T plans to acquire Centennial, a regional provider of wireless and wired communications services, for $944 million in cash. The transaction will enhance AT&T’s wireless coverage for customers in largely rural areas of the Midwest and Southeast United States and in Puerto Rico and the U.S. Virgin Islands. With the addition of Centennial’s wired network in Puerto Rico, AT&T will also be able to better serve the company’s business customers who operate there.

As a result of the acquisition, Centennial’s 1.1 million wireless subscribers — many of them in rural areas — will have access to the wireless network with the best global coverage and to the nation’s premier lineup of innovative wireless devices, including iPhone 3G, an AT&T exclusive. Centennial’s customers who choose select smartphones — such as the BlackBerry® BoldTM, another AT&T exclusive — and AT&T LaptopConnect cards will also enjoy free access to the nation’s largest Wi-Fi network.

“Mobility is a vital investment area for AT&T and our company’s biggest growth driver,” said Ralph de la Vega, president and chief executive officer of AT&T Mobility and Consumer Markets. “This transaction enhances network coverage for our consumer and business customers and is expected to create long-term value for AT&T’s stockholders.”

“This acquisition offers important benefits for wireless customers of both AT&T and Centennial,” de la Vega said. “Our existing customers will enjoy a better on-network calling experience in the current Centennial roaming areas. And Centennial customers will have access to a mobile-to-mobile network of nearly 75 million subscribers, AT&T’s national and international roaming capabilities, our terrific device offerings and our great portfolio of applications and services.”

The Centennial acquisition demonstrates AT&T’s commitment to continuously enhance network quality and coverage for its wireless customers. The addition of Centennial’s high-quality 850 MHz spectrum will improve service quality for AT&T customers in parts of Indiana, Louisiana, Michigan, Mississippi, Ohio and Texas.

Centennial also provides switched voice and high-capacity data and Internet Protocol solutions for business customers in Puerto Rico. The transaction gives AT&T a network presence in Puerto Rico and will allow the company to better serve its multinational business customers with a presence in this U.S. territory.

“Centennial has a 20-year history of doing what is best for our customers, and this transaction is a natural next step for us,“ said Michael J. Small, CEO of Centennial. “As a result of this merger, our wireless customers will enjoy greatly expanded network coverage and access to AT&T’s wide range of innovative products and services. Our business customers will benefit from AT&T’s expertise in delivering networking services and solutions to businesses of all sizes.

“I thank our associates for their dedication and hard work in always rising to the challenges of our rapidly changing industry, and I take pride that our company will become part of a world-class organization like AT&T.“

Under terms of the agreement, Centennial stockholders will receive $8.50 per share for a total equity price of $944 million. Including net debt, the total enterprise value is approximately $2.8 billion. AT&T expects the proposed transaction to deliver significant value to its stockholders. The acquisition offers opportunities for synergies in areas including corporate overhead, advertising, customer care and network operations. In the first year after the transaction closes, AT&T expects minimal dilution to EPS and cash flow, driven by upfront integration costs.

The acquisition is subject to regulatory approval, the approval of Centennial’s stockholders and other customary closing conditions. Welsh, Carson, Anderson & Stowe, Centennial’s largest stockholder, has agreed to vote in support of this transaction. AT&T is working to obtain approvals by the end of the second quarter of 2009.

Centennial’s 1.1 million wireless customers are in Puerto Rico and the U.S. Virgin Islands as well as in Kalamazoo, Cass City, Newaygo, Battle Creek, Benton Harbor, Jackson, Roscommon, Allegan, Grand Rapids, Lansing, Muskegon and Saginaw-Bay City, Mich.; Miami, Kosciusko, Huntington, Kokomo, Muncie, Anderson and Lafayette, Ind.; Lima and Findlay-Tiffin and Williams County, Ohio; Lafayette, Alexandria, Iberville, Bastrop and Lake Charles and Caldwell, West Feliciana, Beauregard and DeSoto parishes, La.; Beaumont-Port Arthur, Texas; and Claiborne and Copiah counties, Miss.

About AT&T

AT&T Inc. (NYSE: T) is a premier communications holding company. Its subsidiaries and affiliates, AT&T operating companies, are the providers of AT&T services in the United States and around the world. Among their offerings are the world’s most advanced IP-based business communications services and the nation’s leading wireless, high speed Internet access and voice services. In domestic markets, AT&T is known for the directory publishing and advertising sales leadership of its Yellow Pages and YELLOWPAGES.COM organizations, and the AT&T brand is licensed to innovators in such fields as communications equipment. As part of its three-screen integration strategy, AT&T is expanding its TV entertainment offerings. In 2008, AT&T again ranked No. 1 on Fortune magazine’s World’s Most Admired Telecommunications Company list and No. 1 on America’s Most Admired Telecommunications Company list.

CERTIFIED ENVIRONMENTAL GROUP INCORPORATED (OTC: CENV)
"Up 75.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CENV.php

Certified Environmental Group develops and commercializes alternative energy solutions focusing on clean drinking water, power and shelter through its fully owned operating subsidiary Global Life Water.

CENV News:

November 10 - Certified Environmental Group Announces Proper Share Structure and Corporate Direction

Certified Environmental Group Inc. (OTC: CENV) and its subsidiary Global Life Water informs its shareholders that the company is moving forward in an aggressive fashion to complete several agreements with large development companies to move forward our company initiative of providing clean drinking water and power to regions less fortunate.

As revealed in its first press release, CENV is working alongside pink sheets to become a reporting company. Many investors have contacted CEG management via phone and email in the last several days asking the current share structure for CENV. Management will be retiring 190,000,000 shares this week to bring the current structure by week's end to the following:

Authorized Shares: 900,000,000
Issued and Outstanding Shares: 551,169,434
Restricted Shares: 504,811,553
Free trading Shares: 46,357,881
Held in CEDE:40,364,183

Management plans to upload a current report from DTCC indicating the current number of shares in "CEDE" as well as update pink sheets with the proper share as soon as the shares have been retired later this week. Certified Environmental Group Inc. has several exciting plans in the works and will continue to keep its shareholders informed.

PUDA COAL (OTCBB: PUDC)
"Up 25.42% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/PUDC.php

Puda Coal, through its subsidiaries in China, supplies premium grade coking coal to the steel making industry for use in making coke. The Company currently possesses 3.5 million metric tons of annual coking coal cleaning capacity in Shanxi Province, China. Shanxi Province provides 20 - 25% of China's coal output and supplies nearly 50% of China's coke.

PUDC News:

November 10 - Puda Coal Announces Strong Third Quarter Results

Q3 Revenue Rises 83% and Net Income Climbs 94% Year over Year

Puda Coal, Inc. (OTCBB: PUDC), a supplier of China's high grade metallurgical coking coal used to make coke for the purposes of steel manufacturing, announced its strong financial results for the quarter ended September 30, 2008.

Third Quarter 2008 Highlights:

* Third quarter revenue reached a record $74.1 million, up 82.7% from the third quarter last year.

* Operating income totaled $9.0 million, up 63.1% from the third quarter last year.

* Net income was $6.5 million or $0.06 per fully diluted share, up 94.3% from $3.4 million, or $0.03 per fully diluted share, for third quarter last year.

* Sales of cleaned coal totaled 603,000 metric tons (MT), up 22.6% from third quarter last year.

* Average selling price of cleaned coal rose 35.2% to approximately $123 per MT (after adjusting for exchange rate differences) from the third quarter last year.

* Launched new corporate website: www.pudacoalinc.com.

* To present at the Rodman & Renshaw Annual Global Investment Conference in New York and conduct non-deal roadshow in the U.S. in November.

"We are extremely pleased with the significant increase in both our top and bottom line performance during the third quarter, which was the result of strong demand for our high grade coking coal and a substantial increase in selling prices," said Mr. Zhu, CEO and President of Puda Coal. "We plan to maintain a strong level of cash flow and liquidity to fuel our operations in the fourth quarter of 2008 and in 2009," added Mr. Zhu.

Results for the Third Quarter 2008

For the quarter ended September 30, 2008, total revenue was $74.1 million, up 82.7% from $40.5 million in the same quarter last year. This revenue growth was driven by larger customer order volume from existing and new clients for high-grade coking coal. Sales of cleaned coal were 603,000 MT, up 22.6% from 492,000 MT in the same period last year. The average selling price was approximately $123 (after adjusting for exchange rate differences), up 35.2% from $91 for the same quarter of 2007. The increases in tonnage sales and selling price of cleaned coal were the primary reasons for the increase in the net revenue.

Gross profit for the quarter was $10.2 million, up 53.1% from $6.7 million for the same period of 2007. Gross margin was 13.8% in the quarter, down from 16.4% in the same period last year. The 2.6 percentage point decline was attributable to an increase in the average purchase price of raw coal, which rose from $56 per ton in the third quarter of 2007 to $90 per ton in the current quarter. The increase in the average price of raw coal was partially offset by the increase in the average selling price of cleaned coal.

Operating expenses for the third quarter of 2008 were $1.2 million, up 5.1% from $1.1 million in the same period last year. Selling expenses increased 12.8% in support of the increase in net revenue, while general and administrative expenses declined 6.6%. As a percentage of net revenue, operating expenses were 1.6% in the third quarter of 2008, compared to 2.8% in the same quarter last year.

Operating income was $9.0 million, or 12.1% of revenue in the third quarter of 2008, up 63.1% from $5.5 million, or 13.6% of net revenue in the third quarter of 2007.

Interest expense and debt financing costs totaled $0.3 million in the third quarter of 2008, down from $0.9 million a year ago. This decrease was primarily due to lower non-cash expenses related to the amortization of the discount on the Company's convertible notes and warrants in the current quarter. In addition, the Company incurred a penalty of $0.4 million in the third quarter of 2007 due to a delay in the effectiveness of the registration statement related to its November 2005 private placement. The penalty was paid in shares of the Company's common stock.

During the third quarters of 2008 and 2007, the Company recorded non-cash gains of $0.1 million and $0.6 million, respectively, for the gain in fair value of the warrants issued in the November 2005 private placement.

Income tax expense increase 21.1% to $2.3 million in the third quarter of 2008 from $1.9 million in the year ago period due to the increase in operating profit at the Company's operating company, Shanxi Coal. This was partially offset by a reduction in the income tax rate to 25% from 33%, effective January 2008.

Net income was $6.5 million, or $0.06 per fully diluted share, compared to $3.4 million, or $0.03 per fully diluted share, in the third quarter of 2007.

Nine Month Results

Net revenue was $177.8 million for the nine months ended September 30, 2008, up 53.2% from $116.0 million in the same period of 2007. Gross profit was $24.3 million, or 13.7% of revenue, up 17.1% from $20.8 million, or 17.9% of revenue, for the nine months ended September 30, 2007. Operating income was $20.4 million, or 11.5% of revenue, up 19.4% from $17.1 million, or 14.7% of revenue, in the first nine months of 2007. Net income was $13.7 million, or $0.13 per fully diluted share, compared with net income of $6.5 million, or $0.07 per fully diluted share, in the nine months ended September 30, 2007.

Financial Condition

As of September 30, 2008, Puda Coal had $39.4 million in cash and cash equivalents and $63.3 million in working capital and a current ratio of 4.0:1. Long-term debt, excluding current portion, was $8.1 million and shareholders' equity stood at $68.3 million up from $48.6 million at the end of 2007.

The Company generated $22.6 million in cash from operating activities for the nine months ended September 30, 2008, compared to cash used in operating activities of $17.4 million in the same period last year. This was primarily due to a decrease in working capital needs resulting from decreased inventory. As of September 30, 2008, the Company had approximately $25.4 million in inventories, of which $12.3 million was raw materials. Business Outlook

Due to high prices for raw materials used in steel making and other economic factors, China's steel industry is currently experiencing slower production, which the Company believes will have a slight impact on its tonnage sales in the next two quarters or a relatively longer time.

In the longer term, Puda Coal believes the outlook for its coal washing operations remains attractive, as the Company has maintained a stable increased customer base and supply tunnels, and the demand for high-grade coking coal will continue to increase due to the development programs of China's western regions, which is expected to drive demand for steel in the long term. The Company is currently operating at approximately 69% utilization and has the capacity to meet the increases in future demand. In addition, the Company intends to execute its strategy of entering the coal mining business to increase profitability.

"While steel production in China is currently experiencing some softness, we believe the ongoing need for steel in China's long-term economic development will continue to drive the demand for steel. This provides significant opportunities for suppliers of cleaned coking coal like us," said Mr. Zhu. "We believe Puda Coal is particularly well positioned to capture this opportunity because of our excellent customer relationships and ability to provide our customers with large quantities of high grade cleaned coal."

Upcoming Events

Puda Coal will present at the upcoming Rodman & Renshaw Annual Global Investment Conference held November 10-12 at the New York Palace Hotel in New York City. During the conference, Puda Coal's management will be available for one-on-one meetings.

To complement its participation at the conference, Puda Coal is participating in a non-deal roadshow from November 10-14. Ms. Laby Wu, Puda Coal's Chief Financial Officer and Mr. Wenwei Tian, Puda Coal's COO and Director of Investor Relations will visit securities analysts and other investors in New York, Chicago and Dallas.

INSMED INCORPORATED (NASDAQ: INSM)
"Up 33.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/INSM.php

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, visit www.insmed.com.

INSM News:

November 10 - Insmed Gains Royalty-Free Worldwide Rights for IPLEX™ in Connection with Potential Expanded Access ALS Programs

Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced that Genentech, Ipsen/Tercica and Insmed jointly issued the following statement:

Genentech, Ipsen/Tercica, and Insmed have been contacted by people living with Amyotrophic Lateral Sclerosis (ALS) and their loved ones seeking access to an IGF-I/IGFBP3 product called IPLEX(TM), which is solely manufactured by Insmed. We understand the devastation a disease like ALS causes and that there are a lack of available therapies that provide meaningful clinical benefit.

Although IPLEX(TM) has not been rigorously tested in people with ALS, nor received regulatory approval for use in ALS, all the companies involved appreciate the urgency and desperation for new treatments in the ALS community. We are all working diligently to determine how best to respond to that need.

The availability of IPLEX(TM) is subject to a Court-Ordered Settlement Agreement. On November 8, 2008, Genentech and Ipsen/Tercica signed a letter of intent whereby they have consented to amend the Court-Ordered Settlement Agreement to permit Insmed to supply IPLEX(TM) in connection with named-patient ALS programs worldwide on a royalty-free basis. Insmed's ability to do so will be dependent on satisfying any regulatory requirements in any country where a request for treatment is made.

Ipsen/Tercica and Insmed also plan to enter into negotiations concerning the development of IPLEX(TM) for the treatment of ALS, subject to analyzing the data from the ALS patients in Italy who have received IPLEX(TM), and satisfying any applicable regulatory requirements.

These actions represent each company's commitment to find a solution to the requests coming from the community of patients and their families. Insmed will update the community as further progress is made.

ABOUT AMYOTROPHIC LATERAL SCLEROSIS

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disease that attacks nerve cells in the brain and spinal cord resulting in muscle weakness and atrophy. The life expectancy of an ALS patient averages about two to five years from the time of diagnosis. For more information about ALS, visit www.alsa.org.

ABOUT IPLEX™

IPLEX(TM) is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug, approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, is currently being investigated in ALS in Italy and in Myotonic Muscular Dystrophy.

DECODE GENETICS INCORPORATED (NASDAQ: DCGN)
"Up 14.71% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DCGN.php

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma. deCODE is delivering on the promise of the new genetics.

DCGN News:

November 6 - deCODE genetics Announces Third Quarter 2008 Financial Results

deCODE Genetics Inc. (Nasdaq: DCGN) announced its consolidated financial results for the quarter ended September 30, 2008. A conference call to discuss the quarter's results, recent operating highlights and a strategic update will be webcast live tomorrow, Friday, November 7, at 8:00am EST/1pm GMT (details below).

Operating loss for the third quarter 2008 was $11.3 million, compared to $22.2 million for the third quarter 2007. Operating loss for the first nine months of 2008 declined to $44.4 million from $65.7 million for the first nine months of 2007.

Net loss for the quarter ending September 30, 2008 was $17.9 million, compared to $24.2 million for the third quarter 2007. Net loss for the first nine months of 2008 was $62.9 million, compared to $63.1 million for the first nine months of last year. In addition to operating loss, net loss figures for the periods presented include interest expense and, in the 2008 periods, unrealized loss resulting from the revaluation of the company's auction rate securities investments. The nine-month figure for 2007 also includes a one-time payment deCODE received related to the settlement of an intellectual property suit.

Basic and diluted net loss per share was $0.29 for the third quarter 2008, compared to $0.40 for the same quarter in 2007. For the first nine months of 2008, basic and diluted net loss per share was $1.03, unchanged from that for the first nine months of last year. At the close of the third quarter 2008, the company had approximately 61.8 million shares outstanding.

Revenue for the third quarter this year was $12.0 million, compared to $10.9 million for the same period a year ago. For the first nine months of 2008, revenue was $42.0 million, compared to $27.1 million for the same period last year. As of September 30, 2008, the company had $17.7 million in deferred revenue that will be recognized over future reporting periods. The period-on-period increase in revenue for the third quarter and first nine months of 2008 was driven principally by growth in the company's genomic services business, which includes the company's diagnostics, deCODEme(TM) personal genome analysis, and contract genotyping businesses.

Research and development expense was $5.7 million for the third quarter of this year, compared to $14.1 million for the same period last year. For the first nine months of 2008, R&D expense was $26.3 million, compared to $41.3 million for the first nine months of 2007. Our research and development expense in the first nine months of this year reflects the conclusion of clinical pharmacology studies in our most advanced drug development programs, preparations for the IND filing for our PDE4 modulator DG071, the launch of our prostate cancer, glaucoma and breast cancer tests, and the advancement of gene and target discovery work in a range of major disease areas.

Selling, general and administrative expense for the third quarter of 2008 was $6.7 million, compared to $7.1 million for the 2007 period. For the first nine months of the year, SG&A expense was $21.0 million in 2008 and $19.4 million in 2007.

At September 30, 2008, the company had liquid funds available for operating activities (cash and cash equivalents together with current investments) of $11.8 million, as compared to $23.7 million at June 30, 2008 and $64.2 million at December 31, 2007. The net utilization of liquid funds in the three and nine-month periods ended September 30, 2008 was $12.0 million and $52.4 million, respectively. At September 30, 2008, the company had $35.5 million in cash, cash equivalents and investments, comprised of the $11.8 million in cash and cash equivalents, as well as $5.5 million in restricted investments in U.S. Treasury Bills and $18.2 million in illiquid, non-current investments in auction rate securities. At December 31, 2007, the company had $94.1 million in cash, cash equivalents, restricted cash equivalents, and investments.

The company is undertaking a review of its long-term business strategy with the goal of sharpening the focus of its business, selling assets, securing partnerships, and utilizing the resources generated to support product development and marketing efforts in its core business. The company has utilized a 30-day grace period for the scheduled October 15 interest payment on its 3.5% Senior Convertible Notes due 2011 and is reviewing methods for making this payment. Given its current liquid assets, and without paying the interest on its Notes from its present funds, the company must obtain further financial resources through either the implementation of strategic alternatives, corporate partnerships, or the sale of or loans secured by its auction rate securities in order to continue operations beyond the end of this year. The company is focused on reducing expenses and speeding the evaluation of its strategic options in order to obtain the resources to do so.

deCODE has significant operations in Iceland and pays a large proportion of its fixed costs in Icelandic krona, while its sales are generally denominated in US dollars and its reporting currency is the US dollar. During the third quarter and beginning of the fourth quarter the global financial crisis caused significant economic turmoil in Iceland. As a result, the value of the Icelandic krona has declined significantly versus the US dollar. The turmoil in the Icelandic financial sector and economy as a whole have not to date had any significant adverse impact on deCODE or its day to day operations. deCODE is monitoring closely the situation in Iceland, the principal impact of which for the company has been to decrease the dollar value of our krona-denominated costs. deCODE's most significant operating expenses denominated in krona include salaries and rental payments on our leased facilities and capital equipment. In as far as the krona decreases in value versus the U.S. dollar that portion of our overall operating expenses that are payable in krona will decrease.

"Over the past few months we have continued to bring forward new products for treating and preventing common diseases. Utilizing the expertise of our protein crystallography and medicinal chemistry units we have filed an IND on an exciting new PDE4 modulator for Alzheimer's disease that has the potential to avoid some of the side effects of earlier compounds. We have also just launched the first DNA-based test for risk of the common forms of breast cancer, a test which promises to improve the way in which we target intensive screening and thus to catch more cancers earlier. At the same, in a global economic climate in which there is limited access to capital for companies of our size, we believe that the best way to develop and capture the value of our capabilities and product portfolio is to sharpen the focus of our business. We are therefore in the process of reviewing our long-term strategy and will be sharing with you the results of this process in the weeks ahead," said Kari Stefansson, CEO of deCODE.

MEMORY PHARMACEUTICALS CORPORATION (NASDAQ: MEMY)
"Up 11.69% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MEMY.php

Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer's disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company's products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer's disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzheimer's disease and CIAS. Its products also comprise PDE4 inhibitors, including MEM 1414, a phase I clinical trial program, as well as MEM 1917 for CNS disorders and depression; PDE10 Inhibitor program; and 5-HT6 Antagonists for the treatment of Alzheimer's disease, schizophrenia, attention deficit disorder, and obesity. The company has collaborations with F. Hoffman-La Roche, Ltd. for the development of nicotinic alpha-7 agonists; and Amgen, Inc. for the development of PDE10 inhibitors. In addition, it has a development agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was founded in 1997 and is based in Montvale, New Jersey.

MEMY News:

November 10 - Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that six abstracts related to its clinical and preclinical programs have been accepted for poster presentations at the 38th Annual Meeting of the Society for Neuroscience in Washington, D.C. from November 15-19, 2008. The abstracts include additional preclinical data for R3487/MEM 3454, the Company's lead nicotinic alpha-7 receptor agonist currently in Phase 2 development for both Alzheimer's disease and cognitive impairment associated the schizophrenia (CIAS), new preclinical data for the Company's lead 5-HT(6) receptor antagonist, MEM 68626, and data from its collaboration with Amgen focused on the development of PDE10 inhibitors.

"We continue to advance the development of novel therapies for the treatment of cognitive disorders and look forward to reporting on the new data emerging from our key programs," stated David A. Lowe, Ph.D., Chief Scientific Officer of Memory Pharmaceuticals. "We and our partner Roche are evaluating R3487/MEM 3454 as a treatment for both Alzheimer's disease and CIAS, and the preclinical data for R3487/MEM 3454 adds to the growing body of evidence suggesting the compound enhances cognition. In addition, MEM 68626 continues to demonstrate efficacy in multiple models of memory, including new findings of enhanced performance in a spatial working memory task. Furthermore, we continue to progress our program focused on advancing PDE10 inhibitors for potential clinical development."

SUNESIS PHARMACEUTICALS INCORPORATED (NASDAQ: SNSS)
"Up 26.51% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SNSS.php

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, visit www.sunesis.com.

SNSS News:

November 6 - Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

Voreloxin Demonstrates Promising Clinical Activity in Patients with Difficult-to-Treat Cancers

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8. Data previously presented from Phase 1 and Phase 1b/2 studies in patients with acute myeloid leukemia (AML) showed that preliminary clinical responses were observed in the relapsed/refractory AML population and the data supports further clinical development for voreloxin both as a single agent and in combination with cytarabine. Preliminary efficacy results previously presented from an ongoing Phase 2 trial demonstrate single agent activity of voreloxin in advanced platinum-resistant ovarian cancer and that the drug is generally well tolerated in this difficult-to-treat patient population.

"We believe that voreloxin has the potential to change the standard of care in AML and platinum-resistant ovarian cancer and look forward to reporting updated results of our AML trials at ASH," said Daniel Swisher, Chief Executive Officer, Sunesis Pharmaceuticals. "Our goal is to advance voreloxin into a pivotal trial in AML by the end of 2009."

Phase 1 and 1b/2 Studies of Voreloxin in AML

Data presented from a completed Phase 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that single agent voreloxin was generally well tolerated, with the most frequently observed dose limited toxicity (DLT) being reversible grade 3/4 oral mucositis. The researchers concluded that single agent activity in the relapsed/refractory AML population supports further clinical development.

Researchers also presented initial data from an ongoing Phase 1b/2 study testing voreloxin in combination with cytarabine. The Phase 1b/2 trial is designed to evaluate safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days.

Of 11 evaluable patients in the first three cohorts, 3 patients have achieved a complete remission (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin) and one had complete remission and one had a complete remission without full platelet recovery.

A copy of this presentation entitled "Voreloxin (SNS-595): An Active Agent in AML" is available at http://www.sunesis.com.

A Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian Cancer

In this ongoing Phase 2 study, 65 women with advanced platinum-resistant ovarian cancer were administered voreloxin at a dose of 48 mg/m2 as a single agent once every three weeks. At this dose, two patients have had a complete response, five have had partial responses and 23 achieved stable disease for 90 days or more. This equates to an overall disease control rate of 46%. Thirty-five women in the Phase 2 study were given 60 mg/m2 once every four weeks. Of the 32 patients evaluable for efficacy at this dose, one patient has had a complete response, two have had partial responses and 20 achieved stable disease thus far.

Voreloxin was also generally well tolerated in platinum-resistant ovarian cancer patients. Grade 3/4 non-hematologic adverse events (greater than or equal to 5%) at the 48 mg/m2 dose were low: fatigue (14%), vomiting (6%) and infections (8%). Low rates of febrile neutropenia occurred in 8% of the 65 patients evaluable for safety at 48 mg/m2 dosed every three weeks and 6% of the 35 patients evaluable for safety at 60 mg/m2 dosed every four weeks. Based on this emerging safety profile and low incidence of febrile neutropenia, the dose of voreloxin has been escalated to 75 mg/m2 dosed every four weeks. Sunesis expects to complete enrollment of the 75 mg/m2 cohort by the end of 2008.

A copy of this presentation entitled "Voreloxin (SNS-595) in Platinum-Resistant Ovarian Cancer" is available at www.sunesis.com.

ABOUT VORELOXIN

Voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site- selective DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

ABOUT ACUTE MYELOID LEUKEMIA

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

ABOUT OVARIAN CANCER

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there will be an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.